BCL2L1 and lung cancer: In line with the tumor reduction, nanoPDLIM2 administration decreased nuclear RelA and STAT3, a hallmark of NF-κB and STAT3 activation, accordingly reduced the expression of their downstream cell survival gene Bcl-xL and cell proliferation gene Cyclin D1, increased apoptosis and decreased proliferation of lung cancer cells (Figure 2C-E).